Literature DB >> 19462806

[Anesthetic management for electroconvulsive therapy in the patients with a history of neuroleptic malignant syndrome].

Keiko Setoyama1, Takao Hirata, Hitoshi Saeki, Yasuhiro Morimoto, Syunsuke Tsuruta, Mishiya Matsumoto, Takefumi Sakabe.   

Abstract

We report three patients with a history of neuroleptic malignant syndrome for whom modified electroconvulsive therapy (m-ECT) was scheduled. Two patients suffered from schizophrenia, and one suffered from depression. Their symptoms, such as hyperthermia, consciousness disturbance, myotonus, tremor, sweating, and tachycardia, improved gradually with administration of dantrolene and fluid infusion. However, their psychotic state was exacerbated. Therefore, m-ECT was scheduled. When patients were restless at the hospital ward, they were sedated with propofol and transferred to the operating room. General anesthesia was induced with thiopental 2.5-5 mg x kg(-1). After loss of consciousness, vecuronium bromide 0.01 mg x kg(-1) followed by a dose of 0.1 mg x kg(-1) was administered and ventilation was assisted using a face mask and 100% oxygen. After the ECT stimulus, the patients were sedated with propofol until full recovery from muscle relaxation. Although anesthesia time (mean 38 min) was slightly longer (19 min) than in those anesthetized with thiopental and suxamethonium chloride, m-ECT was performed safely and effectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462806

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  2 in total

1.  Use of rocuronium-sugammadex, an alternative to succinylcholine, as a muscle relaxant during electroconvulsive therapy.

Authors:  Hiroko Hoshi; Yuji Kadoi; Jiro Kamiyama; Akiko Nishida; Hiroyuki Saito; Masaki Taguchi; Shigeru Saito
Journal:  J Anesth       Date:  2011-02-04       Impact factor: 2.078

2.  Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy.

Authors:  Yuji Kadoi; Hiroko Hoshi; Akiko Nishida; Shigeru Saito
Journal:  J Anesth       Date:  2011-09-24       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.